The Boron–Neuron Connection: The Potential of Boron‐Containing Molecules for Treating Incurable Amyotrophic Lateral Sclerosis
ChemMedChem · 2026-11-12 · 21 (21)
DOI: 10.1002/cmdc.70554 ↗At a glance
Übersichtsarbeit in ChemMedChem, published online on 2026-10-27. Written by Nitesh Sanghai and 5 co-authors. Institution: College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. Major MEDLINE topics: Amyotrophic Lateral Sclerosis, Neuroprotective Agents, Boron Compounds, Neurons. 239 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council of Canada (NSERC).
Abstract (original language)
Background
Boron (B), a group 13 metalloid, has emerged as a versatile element at the intersection of chemistry, biology, and medicine. Its electron‐deficient nature and ability to reversibly interconvert between trigonal planar ( sp 2 ) and tetrahedral ( sp 3 ) geometries enable dynamic covalent interactions with biological nucleophiles, making boron‐containing compounds (BCCs) attractive pharmacophores that selectively interact with reactive oxygen species (ROS) and are ROS‐responsive for therapeutic development. BCCs possess antioxidant, anti‐inflammatory, and metal‐chelating properties that make them attractive candidates for neurodegenerative diseases. Amyotrophic lateral sclerosis (ALS), a fatal and multifactorial motor neurodegenerative disorder, is characterized by oxidative stress, neuroinflammation, mitochondrial dysfunction, and metal dyshomeostasis, providing a strong rationale for exploring boron‐based therapeutics.
Methods
This review examines current literature on B chemistry, pharmacology, and translational applications, with emphasis on mechanisms relevant to ALS pathogenesis. This review focuses on ROS‐responsive B scaffolds, blood–brain barrier (BBB) permeability, neuroprotective mechanisms, hormonal modulation, metal chelation, and emerging preclinical evidence supporting boron‐based interventions.
Conclusions
BCCs represent a promising yet underexplored therapeutic platform for ALS and related neurodegenerative disorders. Their ROS‐responsive, redox‐modulating, and neuroprotective properties, combined with favorable CNS drug‐like pharmacokinetics, offer a mechanistically distinct approach to disease modification. Emerging preclinical evidence strongly supports further translational investigation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
ORCID profiles: Nitesh Sanghai, Billy Vuong, Muhammad Shaharyar K Afridi, Sasha Leggett, Hemin Roghzai, Geoffrey K Tranmer
Funding
- Canadian Institutes of Health Research (CIHR)
- Natural Sciences and Engineering Research Council of Canada (NSERC)
Cite
APA
Sanghai, N., Vuong, B., Afridi, M. S. K., Leggett, S., Roghzai, H., & Tranmer, G. K. (2026). The Boron–Neuron Connection: The Potential of Boron‐Containing Molecules for Treating Incurable Amyotrophic Lateral Sclerosis. ChemMedChem, 21(21). https://doi.org/10.1002/cmdc.70554
Vancouver
Sanghai N, Vuong B, Afridi MSK, Leggett S, Roghzai H, Tranmer GK. The Boron–Neuron Connection: The Potential of Boron‐Containing Molecules for Treating Incurable Amyotrophic Lateral Sclerosis. ChemMedChem. 2026;21(21). doi:10.1002/cmdc.70554
BibTeX
@article{Sanghai2026,
author = {Sanghai, Nitesh and Vuong, Billy and Afridi, Muhammad Shaharyar K and Leggett, Sasha and Roghzai, Hemin and Tranmer, Geoffrey K},
title = {The Boron–Neuron Connection: The Potential of Boron‐Containing Molecules for Treating Incurable Amyotrophic Lateral Sclerosis},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {21},
doi = {10.1002/cmdc.70554}
}
EUVIMED